GLP-1 receptor agonists market is anticipated to showcase a considerable CAGR during the forecast period. The increasing R&D and huge investment by the major market players for the development of new products along with the high prevalence of type 2 diabetic patients across the globe are the key factors responsible for the high growth of the GLP-1 receptor agonists market across the globe. GLP-1 receptor agonists are a category of antidiabetic agents that performs functioning of the glucagon-like peptide. GLP-1 is a natural incretin compound that influences the body functioning once they get released from the gut during digestion.
Browse the full report description Global Glucagon-Like Peptide-1 (GLP-1) Receptor agonists Market Size, Share & Trends Analysis Report by Drug Type (Exenatide (Bydureon, Byetta), LiraglutidE (Victoza), Lixisenatide (Lyxumia), and Dulaglutide (Trulicity)) Forecast Period (2020-2026) at https://www.omrglobal.com/industry-reports/glucagon-like-peptide-1-glp-1-receptor-agonists-market
The combination of GLP-1 receptors, GLP-1 agonists, and endogenous GLP-1 is capable to reduce blood glucose levels to facilitate Type 2 diabetes patients to reach glycemic control. The proper intake of the GLP-1 receptor agonists increases the glucose-dependent secretion of insulin from functioning beta cells. Moreover, its intake decreases the glucagon release after meals, decrease hepatic glucose production, delayed gastric emptying, suppress the appetite and promotes beta-cell proliferation. According to the International Diabetic Federation (IDF) in 2019, nearly 463 million adults (20-79 years) were living with diabetes across the globe and this figure is anticipated to reach 700 million by 2045.
Diabetes is responsible for nearly $760 billion in health expenditure in 2019 that resembles 10% of total spending on adults for their health treatment. In 2019, 374 million people are observed to be at an increased risk of developing type 2 diabetes. The considerably high prevalence of this chronic disorder is creating the demand for the market growth of the GLP-1 receptor agonists. Bristol Mayer Squibb, Novo Nordisk A/S, Sanofi SA, Eli Lilly & Company, AstraZeneca PLC, and Merck & Co., Inc are the key players operating in the global GLP-receptor agonists market that are making hefty investments in the R&D of new drugs. Moreover, these players are actively adopting other growth strategies such as mergers & acquisitions, strategic agreements, partnerships, and collaborations in order to remain competitive in the global GLP-1 receptor agonists market.
Recent Development in the market
In September 2019, the US FDA had approved Rybelsus (semaglutide) oral tablets prepared by the Novo Nordisk A/S, a pharmaceutical company to improve the control of blood sugar levels in adult patients with type 2 diabetes, along with diet and exercise. Rybelsus is the first GLP-1 receptor protein treatment approved for use in the US that does not need to be injected. GLP-1 drugs are non-insulin treatments for people with type 2 diabetes.
Global GLP-1 Receptor Agonists Market Segmentation
By Drug Type
Global GLP-1 Receptor Agonists Market – Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy
@ https://www.omrglobal.com/request-sample/glucagon-like-peptide-1-glp-1-receptor-agonists-market